Office of Health Economics

health economics hta pharmaceuticals uk medicines health care innovation eq-5d nhs pricing biotechnology and pharmaceuticals nice htai pharmaceutical industry r&d england ohe adrian towse ispor cancer health technology assessment reimbursement qaly europe medicine proms quality of life antibiotics cost-effectiveness presentation incentives patients health outcomes health policy value-based pricing drugs emerging markets diagnostics devlin ispor europe 2018 indication-based pricing intellectual property pharmaceutical innovation hepatitis c discrete choice experiment stated preferences children preferences end of life economics decision modelling İçer eq-5d-y patient-reported outcomes access antimicrobial resistance amr drug development qalys prescription drug france germany costs vbp competition research euroqol risperidone net monetary benefit life-cycle value public preferences 2018 multi-indication pricing research and development measurement for drugs affordability utilities orphan drugs direct acting antivirals adolescents cost-effectiveness analysis mental health transparency open source presentations health status tto health care systems mlics discrete choice end-of-life rare diseases genomics differential pricing access to care elderly wellbeing costa rica prices patient reported outcomes value medical research quality risk public asia spillovers policy outcomes dying death dead health state valuation health poster internet survey generic competition social surplus second generation antipsychotics italy sweden procurement contracting antipsychotics surplus innovative medicine financial incentives national health service specialised care pay-for-performance payers novel elements of value real option value hta decision making mcda weighted cea augmented cea weighted qalys value in health decision analysis modeling healthcare data analytics next generation sequencing genomic testing oncology lung cancer outcomes-based contracting real world evidence royal brompton legitimate legal bases consent gdpr health data legal barriers innovative payment models indication specific pricing indication based pricing stated preference professional training health financing universal health coverage value of knowing value of diagnostic information third plenary session expenditure caps expenditure impact buget indication-based-pricing debate ispor barcelona welfare states patient-centred care fair pricing world health organisation heath technology assessment (hta) globalisation barcelona ispor 2018 curative therapies challenges rewards payors regulators triangulating developers handling uncertainty payment mechanisms evidence uncertainty hta outcomes hta transferability patient involvement flexibility and transparency hta lifecycle therapeutic added value future directions modern hta good practice pharmaceutical r&d. value-based pricing and reimbursement pharmacoeconomics multi-indication drugs indication-specific pricing washington dc ispor summit nancy devlin qaly's lou garrison ipor washing dc approaches to value assessment labour productivity learning outcomes international volunteering global engagement price discrimination indication price and reimbursement pharmaceutical regulation market competition health system capacity daas matching mapping uptake curves static and dynamic efficiency market access r&d incentives supplementary patent certificates economics of r&d rates of return cost-effectiveness threshold revenue cost of r&d fairness qualitative analysis interviews uptake economics of cures methodology visual analogue scale time trade-off valuation markov screening diabetic retinopathy real-world data real-world evidence vaccines framing effects clinical evaluation systematic review cadth sustainability proms conference koonal shah oncology medicines outcome-based payments tto valuations of health states eq-5d-5l eq-5d-3l end of life medicines koonal healtcare decision making cea uhc pbrsa hip surgery us cost effectiveness icer uae ed-5d health care costs pprs ldcs global health mhra ema generics biosimilars latin america end-of-life care burden of illness heor time trade off antimicrobials resistance antibacterials personalized medicine patient access schemes public attitudes caregiving long-term care technology pharmaceutical big data stratified medicine unmet need aai medicare health insurance usa taiwan china brazil health inequality inequality pharm international comparisons forecast clinical trial cost assessment australia ispe disease management politics commissioning funding kings fund eq-vas